Aclaris Therapeutics, Inc. (ACRS) vs Altimmune, Inc. (ALT)
Aclaris Therapeutics, Inc. and Altimmune, Inc. are both Biotechnology companies. Aclaris Therapeutics, Inc. and Altimmune, Inc. are of similar size ($593.3M and $589.0M). Altimmune, Inc. grew revenue faster over the last twelve months: 130.0% against −51.0%. Altimmune, Inc. has the higher net margin (0.00% vs −921.5%) and the higher return on invested capital (−34.3% vs −163.4%). Across the 18 metrics below, Altimmune, Inc. leads on 10 and Aclaris Therapeutics, Inc. on 8.
Valuation
Profitability
| Metric | ACRS | ALT | Biotechnology median |
|---|---|---|---|
| Gross margin | 12.90% | 100.00% | 65.16% |
| Operating margin | (1,050.16%) | 0.00% | 0.00% |
| Net margin | (921.50%) | 0.00% | 0.00% |
| Free cash flow margin | (756.50%) | 0.00% | 0.00% |
| Return on equity | (59.10%) | (28.87%) | (57.72%) |
| Return on assets | (41.07%) | (25.58%) | (49.22%) |
| Return on invested capital | (163.35%) | (34.30%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack